# Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine

> **NCT00503594** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 92 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Methotrexate and temozolomide
- **DRUG:** Methotrexate , procarbazine ,vincristine ,cytarabine

## Key facts

- **NCT ID:** NCT00503594
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** 2010-07
- **Final completion:** 2012-07
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503594, "Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00503594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*